Natera, Inc. Q4 FY2024 earnings call

Financials showed Q4 revenues at $476M, up 53% YOY; gross margins 63%; cash flow $46M in Q4. Milestones included innovation roadmap announcement, ASCO GI data, and expanded Medicare coverage for lung cancer. Reimbursement efforts focused on securing biomarker law coverage, AI tools for claims, and over $10M in data contracts. Clinical trials included PEDAL and DEFINE in organ health, CALGB/SWOG 80702 in oncology, and FIND study in early cancer detection.

In Q4 2024, Natera's revenues reached $476 million, a 53% year-on-year increase. Gross margins were 63%, significantly higher than the 51% from the prior year. Excluding true-ups, gross margin was 59%. Women's health saw strong organic growth with clinical validation of the fetal RhD test and new studies in organ health. Organ health volumes were up nearly 50% year-on-year. Oncology's Signatera had clinical volumes up ~60% vs Q4 2023, with Medicare coverage for non-small cell lung cancer and positive results from the CALGB/SWOG 80702 study. Early cancer detection had prospective validation of technology and kick-off of an FDA-enabling study.

Revenue guidance is $1.87B to $1.95B for 2025, driven by volume growth in various segments with upside from ASP growth and coverage. Gross margin guidance presumes continued progress above 59% ex true-ups. R&D and SG&A investments are focused on innovation, with emphasis on MRD, women's health, and early detection.

Gross margin could face short-term headwinds from new product uptake. Reimbursement of biomarker laws and NCCN guideline traction may be slow. Competition with different technologies could impact market share, though Natera's proprietary tech and data provide an edge.

Q: Doubts on Signatera ASP and genome product reception A: Steve Chapman said ASPs could double with increased coverage; Solomon Moshkevich noted genome product is well-received by pharma/biotech for clinical research.

Q: Signatera volume growth and true-ups A: Mike Brophy stated guide presumes growth above 8,000-10,000 units; true-ups will moderate as collections improve.

Q: NCCN guidelines and advanced adenoma data A: Steve Chapman and Alexey Aleshin discussed positive oncologist feedback on NCCN; advanced adenoma data shows no degradation due to prospective sample collection.

Q: Biomarker bills and R&D spend A: John Fesko mentioned slow but improving reception of biomarker bills; R&D spend is focused on oncology, women's health, and early detection.

Q: Early cancer detection timing and platform A: Steve Chapman stated 18-month trial with data expected by end of 2026; platform is scalable for other cancers.